SCPE $15.84 0%
ARMK $36.96 -0.6452%
WHLR $0.85 1.1905%
RCSL3.SA $1.60 -4.1916%
ZED.L $5.00 0%
FTAI-PB $24.26 0%
8257.HK $0.12 7.4074%
1752.HK $0.07 0%
JOET $26.91 -0.2816%
BML-PG $20.23 0.8801%
GBT $68.49 0%
2885.HK $0.31 -8.8235%
CPZ $14.93 0.1006%
BSMX $5.46 0%
ALECR.PA $22 200.00 0%
CAD.L $2.00 0%
CAMP $1.67 -2.9128%
UMI $32.95 0.1532%
3378.HK $2.24 0%
BMV.L $1.35 -3.5714%
1705.HK $0.30 0%
ALUVI.PA $5.02 5.6842%
0RD1.L $258.23 -2.8535%
XMVM $40.90 -0.523%
8062.HK $0.20 0%
1431.HK $0.15 0%
SCM $14.71 0.2386%
0880.HK $3.62 -1.6304%
TAM.L $460.00 -1.0753%
2360.HK $2.08 -1.4218%
PBW $35.63 -1.1376%
DAO $4.95 -21.7994%
6168.HK $0.16 0%
IVLU $25.23 -0.4538%
MEC $10.91 -1.4015%
NUE $138.22 0.5163%
CS $0.84 -0.4013%
INNV $6.28 -0.159%
AASI.PA $30.93 -0.347%
NGACU $9.26 0%
NBPE.L $1 560.00 -0.6369%
FRX $12.00 0%
LEGR $36.63 -0.8929%
INFL $30.24 -0.2145%
IBTX $29.44 -1.3735%
LNN $119.76 -1.0902%
FBRT $12.85 -0.6187%
BSEA $20.67 0.1221%
SCCB $24.50 -0.3255%
KAIRW $0.00 0%
GDV $20.32 -0.6843%
PSCI $93.28 -0.013%
GLDA.L $6 415.50 0.0312%
WAFU $2.14 4.3903%
1428.HK $1.53 -1.9231%
ISBC $13.87 0%
BIOT $10.15 0%
QUAD $3.24 5.8824%
IGEA.L $87.50 -0.506%
0LHY.L $29.00 -0.0259%
CYA $7.59 0.2642%
CE2D.L $5 156.00 -1.1977%
MYNA $7.00 -6.1662%
AKTS $2.66 -2.3897%
SLCR $7.99 41.4159%
FRC-PM $1.73 0%
8042.HK $0.09 0%
1296.HK $1.07 0%
AIU $1.07 3.8835%
1433.HK $0.05 -4.1667%
MDXH.BR $0.35 -2.4862%
ICE $108.23 -0.0046%
EWZS $13.04 0.4623%
TECTP $10.00 0.1001%
ARMP $1.45 11.5308%
MRW.L $286.40 0%
XSEN.L $3 263.50 0.7642%
CBDX.L $3.80 -4.1535%
GBLO $26.56 0%
HPCO $0.59 -4.8387%
GPACU $10.83 0%
RH $259.17 -2.2056%
NTCT $29.64 1.7508%
TTP $26.42 0.1554%
PBRT.L $499.48 0.5182%
GOAC $10.01 0%
SITC-PA $24.25 -0.0824%
BLBD $26.80 38.6646%
XDWD.L $86.97 -0.2466%
PMGMW $0.06 0%
EYPT $5.81 -8.9028%
LUB $1.78 0%
ALHEO.PA $1.90 5.5556%
1817.HK $2.00 0%
0297.HK $1.07 -4.4643%
FTI $13.93 -1.0653%
RF.PA $64.15 0%
VIVLX $32.18 0%
1650.HK $0.06 3.4483%
SIG $72.12 0.5157%
Eng
Логотип
Eng
Лого

Oryzon Genomics S.A. 0RDB.L

$2.10

-$0.01 (-0.24%)
На 18:02, 12 мая 2023

Ранг: 3

Ранг - это оценка кредитоспособности корпорации.

Ключевые показатели

  • Marketcap

    787377.00000000

  • week52high

    2.98

  • week52low

    2.16

  • Revenue

  • P/E TTM

    0

  • Beta

    0.98702200

  • EPS

    -0.08800000

  • Last Dividend

    0.28500000

  • Next Earnings Date

    07 мая 2023 г. в 04:57

Описание компании

Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.

Свежие комментарии

Оставьте свой голос

Анонимное голосование

Будет ли рост российского рынка к концу года?

  • Да

    87%

  • Нет

    12%

Проголосовал 8 человек